Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice

Nutrients. 2019 Aug 15;11(8):1918. doi: 10.3390/nu11081918.


Native hypovitaminosis D (n-hVITD) is frequently found from the early stages of chronic kidney disease (CKD) and its prevalence increases with CKD progression. Even if the implications of n-hVITD in chronic kidney disease-mineral bone disorder (CKD-MBD) have been extensively characterized in the literature, there is a lot of debate nowadays about the so called "unconventional effects" of native vitamin D (25(OH)VitD) supplementation in CKD patients. In this review, highlights of the dimension of the problem of n-hVITD in CKD stages 2-5 ND patients will be presented. In addition, it will focus on the "unconventional effects" of 25(OH)VitD supplementation, the clinical impact of n-hVITD and the most significant interventional studies regarding 25(OH)VitD supplementation in CKD stages 2-5 ND.

Keywords: CKD; cardiovascular risk; mineral metabolism; vitamin D; vitamin D supplementation.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / blood
  • Dietary Supplements* / adverse effects
  • Humans
  • Prevalence
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / diagnosis
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / epidemiology
  • Risk Factors
  • Treatment Outcome
  • Vitamin D / adverse effects
  • Vitamin D / analogs & derivatives*
  • Vitamin D / blood
  • Vitamin D / therapeutic use
  • Vitamin D Deficiency / blood
  • Vitamin D Deficiency / diagnosis
  • Vitamin D Deficiency / drug therapy*
  • Vitamin D Deficiency / epidemiology


  • Biomarkers
  • Vitamin D
  • 25-hydroxyvitamin D